Compare YPF & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YPF | INCY |
|---|---|---|
| Founded | 1977 | 1991 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4B | 17.0B |
| IPO Year | 1995 | 1994 |
| Metric | YPF | INCY |
|---|---|---|
| Price | $50.30 | $115.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 21 |
| Target Price | $45.67 | ★ $103.52 |
| AVG Volume (30 Days) | 1.6M | ★ 1.7M |
| Earning Date | 05-08-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 4173.33 |
| EPS | N/A | ★ 1.47 |
| Revenue | N/A | ★ $3,394,635,000.00 |
| Revenue This Year | $14.39 | $10.44 |
| Revenue Next Year | N/A | $10.99 |
| P/E Ratio | ★ N/A | $78.62 |
| Revenue Growth | N/A | ★ 13.67 |
| 52 Week Low | $22.82 | $69.26 |
| 52 Week High | $57.49 | $119.60 |
| Indicator | YPF | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 56.28 | 58.06 |
| Support Level | $33.57 | $98.50 |
| Resistance Level | $56.82 | $118.97 |
| Average True Range (ATR) | 1.49 | 3.10 |
| MACD | 0.41 | -0.43 |
| Stochastic Oscillator | 95.39 | 50.11 |
YPF SA is an Argentina-based integrated oil and gas company. The company operates through four business segments: Upstream, Midstream and Downstream, LNG and Integrated Gas, and New Energies. The Upstream segment focuses on the exploration and production of crude oil and natural gas. The Midstream and Downstream segment includes refining, transportation, and commercialization of crude oil, refined, and petrochemical products. The LNG and Integrated Gas segment is involved in natural gas transportation, processing, storage, and commercialization. The New Energies segment focuses on energy transition initiatives, including natural gas distribution, power generation, renewable energy, and related technology development. It generates majority of revenue from Midstream and Downstream segment.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.